Meitav Investment House’s Ovid Therapeutics OVID Stock Holding History

Meitav Investment House’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-14,000	Closed	-$80K	–	451
2020 Q3	$80K	Buy	+14,000	New	+$93.7K	﹤0.01%	389

Other funds holding OVID

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Meitav Investment House's OVID Position: Q4 2020 in Review

Meitav Investment House sold out of Ovid Therapeutics (OVID) in Q4 2020, closing a stake of 14,000 shares — an estimated $80K sold.

Meitav Investment House first reported a position in OVID in Q3 2020 and held it in 1 quarter. The position peaked at $80K in Q3 2020. 83 funds tracked by Wall St. Rank hold OVID as of Q4 2020.

Meitav Investment House reported no remaining Ovid Therapeutics position as of Q4 2020 after selling out during the quarter.
Meitav Investment House sold 14,000 Ovid Therapeutics shares in Q4 2020, an estimated $80K.
Meitav Investment House first reported a position in Ovid Therapeutics in Q3 2020 and held it in 1 quarter.
Meitav Investment House's Ovid Therapeutics position peaked at $80K in Q3 2020.
83 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2020.

Based on Meitav Investment House's 13F filing for Q4 2020, filed 2 Feb 2021.